The promise of targeted α-particle therapy

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Mulford, Deborah A ^a   Scheinberg, David A ^a   Jurcic, Joseph G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Radioimmunotherapy; Radiolabeled monoclonal antibodies; Targeted particle therapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; CHELATING AGENT; CYTARABINE; LEAD 212; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUM195; RADIOISOTOPE; RADIUM; RADIUM 223; TERBIUM; TERBIUM 149; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALPHA RADIATION; ANALGESIA; BREAST CANCER; CELL KILLING; CLINICAL TRIAL; COLON CARCINOMA; DOSIMETRY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG SAFETY; ELECTRON; FEASIBILITY STUDY; GLIOMA; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; LYMPHOMA; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; REVIEW; TUMOR CELL; ANIMAL; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; METHODOLOGY; NEOPLASM; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 14844340282     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35:373-379.
2. McDevitt MR, Sgouros G, Finn RD. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
3. Nunez MI, Villalobos M, Olea N, et al. Radiation-induced DNA double-strand break rejoining in human tumour cells. Br J Cancer. 1995;71:311-316.
4. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol. 1994;72:471-474.
5. Pandita TK, Lieberman HB, Lim DS, et al. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene. 2000;19:1386-1391.
6. Munro TR. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res. 1970;42:451-470.
7. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl). 1988;29:631-658.
8. Gadbois DM, Crissman HA, Nastasi A, et al. Alterations in the progression of cells through the cell cycle after exposure to alpha particles or gamma rays. Radiat Res. 1996;146:414-424.
9. Woloschak GE, Chang-Liu CM. Differential modulation of specific gene expression following high- and low-LET radiations. Radiat Res. 1990;124:183-187.
10. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767-1773.
11. Koch L, Apostolidis C, Molinet R, et al. Production of Bi-213 and Ac-225, α-Immuno '97 Symposium Proceedings. Joint Research Centre, Institute for Transuranium Elements (ITU). Karlsruhe, Germany: 1998:20-25.
12. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
13. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot. 1999;50:895-904.
14. Ma D, McDevitt MR, Finn RD, Scheinberg DA. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Appl Radiat Isot. 2001;55:463-470.
15. 224Ra. Int J Rad Appl Instrum [A]. 1988;39:283-286.
16. Larsen RH. Biomedical application of alpha-particle-emitting radium-223. 225th American Chemical Society National Meeting. March, 23-27, 2003:40; New Orleans, LA. Abstract 11.
17. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Res. 2000;6:1433-1455.
18. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Rad Appl Instrum [A]. 1988;39:227-232.
19. Yao Z, Garmestani K, Wong KJ, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med. 2001;42:1538-1544.
20. 2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149-7153.
21. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024 -1026.
22. Huneke RB, Pippin CG, Squire RA, et al. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992;52:5818-5820.
23. Humm JL, Roeske JC, Fisher DR, Chen GT. Microdosimetric concepts in radioimmunotherapy. Med Phys. 1993;20:535-541.
24. 212Bi-labeled antibody. Cancer Res. 1990;50(suppl):985s-988s.
25. 206Bi in the normal rat. Radiat Res. 1975;63:443-454.
26. 212Bi-anti-Tac. Cancer Res. 1994;54:4362-4370.
27. Kennel SJ, Stabin M, Roeske JC, et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res. 1999;151:244-256.
28. Ballangrud AM, Yang WH, Charlton DE, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 2001;61:2008-2014.
29. 90Y. Int J Radiat Oncol Biol Phys. 1984;10:341-348.
30. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res. 1999;59:2635-2643.
31. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999;40:166-176.
32. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
33. Burke JM, Jurcic JG, Divgi CR, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-labeled anti-CD33 monoclonal antibody HuM195 in acute myeloid leukemia (AML) [abstract]. Blood. 2002;100:339.
34. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth-213-labeled anti-CD45 radioimmunoconjugate to condition dots for nonmyeloablative allogeneic marrow grafts. Blood. 2002;100:318-326.
35. Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood. 2003;101:5068-5075.
36. Zalutsky MR, McLendon RE, Garg PK, et al. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
37. Zalutsky MR, Cokgor I, Akabani G, et al. Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients [abstract]. Proc Am Assoc Cancer Res. 2000;41:544.
38. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
39. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
40. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-stretavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.